Adaptimmune Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Marketable securities - available-for-sale debt securities

Marketable securities - available-for-sale debt securities

6 Months Ended

Jun. 30, 2025

Marketable securities - available-for-sale debt securities

Marketable securities - available-for-sale debt securities

Note 7 — Marketable securities – available-for-sale debt securities

As of June 30, 2025, the Company had no investments in marketable securities.

The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of June 30, 2025 and December 31, 2024 are as follows:



	June 30, 2025						December 31, 2024
	Fair market value of investments in an unrealized loss position		Number of investments in an unrealized loss position		Unrealized losses		Fair market value of investments in an unrealized loss position		Number of investments in an unrealized loss position		Unrealized losses
Marketable securities in a continuous loss position for less than 12 months:
Corporate debt securities	$	—		—	$	—	$	4,679	$	2	$	(3)
	$	—		—	$	—	$	4,679	$	2	$	(3)

During the six months ended June 30, 2025, the Company sold investments in marketable securities with a principal of $4,940,000 (based on the specific identification method) for proceeds of $4,940,000.